It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green whileNSTM’s FA Score has 0 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 4 TA indicator(s) are bullish.
IDXX (@Medical Specialties) experienced а -7.11% price change this week, while NSTM (@Medical Specialties) price change was -69.75% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.64%. For the same industry, the average monthly price growth was -0.19%, and the average quarterly price growth was -1.08%.
IDXX is expected to report earnings on Feb 10, 2025.
NSTM is expected to report earnings on Nov 04, 2024.
Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
IDXX | NSTM | IDXX / NSTM | |
Capitalization | 44.8B | 10.6M | 422,642% |
EBITDA | 1.22B | -758.27K | -160,629% |
Gain YTD | -25.055 | -80.763 | 31% |
P/E Ratio | 52.87 | N/A | - |
Revenue | 3.66B | 12K | 30,508,333% |
Total Cash | 454M | 40.6K | 1,118,227% |
Total Debt | 1.07B | 358K | 298,045% |
IDXX | NSTM | ||
---|---|---|---|
OUTLOOK RATING 1..100 | 52 | 91 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 84 Overvalued | 51 Fair valued | |
PROFIT vs RISK RATING 1..100 | 64 | 100 | |
SMR RATING 1..100 | 18 | 97 | |
PRICE GROWTH RATING 1..100 | 63 | 98 | |
P/E GROWTH RATING 1..100 | 75 | 100 | |
SEASONALITY SCORE 1..100 | 46 | 65 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
NSTM's Valuation (51) in the null industry is somewhat better than the same rating for IDXX (84) in the Medical Specialties industry. This means that NSTM’s stock grew somewhat faster than IDXX’s over the last 12 months.
IDXX's Profit vs Risk Rating (64) in the Medical Specialties industry is somewhat better than the same rating for NSTM (100) in the null industry. This means that IDXX’s stock grew somewhat faster than NSTM’s over the last 12 months.
IDXX's SMR Rating (18) in the Medical Specialties industry is significantly better than the same rating for NSTM (97) in the null industry. This means that IDXX’s stock grew significantly faster than NSTM’s over the last 12 months.
IDXX's Price Growth Rating (63) in the Medical Specialties industry is somewhat better than the same rating for NSTM (98) in the null industry. This means that IDXX’s stock grew somewhat faster than NSTM’s over the last 12 months.
IDXX's P/E Growth Rating (75) in the Medical Specialties industry is in the same range as NSTM (100) in the null industry. This means that IDXX’s stock grew similarly to NSTM’s over the last 12 months.
IDXX | |
---|---|
RSI ODDS (%) | 1 day ago65% |
Stochastic ODDS (%) | 6 days ago71% |
Momentum ODDS (%) | N/A |
MACD ODDS (%) | 6 days ago60% |
TrendWeek ODDS (%) | 1 day ago67% |
TrendMonth ODDS (%) | 1 day ago68% |
Advances ODDS (%) | 23 days ago70% |
Declines ODDS (%) | 8 days ago68% |
BollingerBands ODDS (%) | 1 day ago67% |
Aroon ODDS (%) | 1 day ago70% |
A.I.dvisor indicates that over the last year, IDXX has been loosely correlated with MYGN. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if IDXX jumps, then MYGN could also see price increases.
Ticker / NAME | Correlation To IDXX | 1D Price Change % | ||
---|---|---|---|---|
IDXX | 100% | +0.35% | ||
MYGN - IDXX | 48% Loosely correlated | -1.23% | ||
TMO - IDXX | 45% Loosely correlated | +0.96% | ||
AZTA - IDXX | 42% Loosely correlated | +2.82% | ||
BLFS - IDXX | 42% Loosely correlated | +1.41% | ||
WAT - IDXX | 42% Loosely correlated | -0.04% | ||
More |
A.I.dvisor indicates that over the last year, NSTM has been loosely correlated with SNN. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if NSTM jumps, then SNN could also see price increases.
Ticker / NAME | Correlation To NSTM | 1D Price Change % | ||
---|---|---|---|---|
NSTM | 100% | +19.80% | ||
SNN - NSTM | 43% Loosely correlated | +0.16% | ||
TFX - NSTM | 39% Loosely correlated | -1.84% | ||
IDXX - NSTM | 27% Poorly correlated | -0.62% | ||
TRXO - NSTM | 27% Poorly correlated | N/A | ||
XVIPF - NSTM | 22% Poorly correlated | N/A | ||
More |